N. Restifo

F. Marincola, D. Venzon, D. White, 1995, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Immunization of Patients with Metastatic Melanoma Using Both Class I- and Class II-Restricted Peptides from Melanoma-Associated Antigens

S. Rosenberg, P. Hwu, J. Yang, 2003, Journal of immunotherapy.

Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen.

S. Rosenberg, P. Hwu, J. Yang, 2003, Human gene therapy.

A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer.

W. Burns, S. Rosenberg, R. Morgan, 2014, Human gene therapy.

Immunological and Antitumor Effects of IL-23 as a Cancer Vaccine Adjuvant1

Anna M. Keller, B. Blom, R. Kastelein, 2006, The Journal of Immunology.

Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model.

B. Moss, S. Rosenberg, M. Carroll, 1997, Vaccine.

Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors.

S. Rosenberg, K. Irvine, E. P. Shulman, 1997, Journal of the National Cancer Institute.

Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes.

B. Moss, S. Rosenberg, K. Irvine, 1999, Proceedings of the National Academy of Sciences of the United States of America.

Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD 8 + T cells

S. Rosenberg, N. Restifo, L. Gattinoni, 2007 .

Toll-like Receptors inTumor Immunotherapy

S. Rosenberg, N. Restifo, L. Gattinoni, 2007 .

Defining ‘T cell exhaustion’

E. Wherry, T. Schumacher, W. Haining, 2019, Nature Reviews Immunology.

T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy

B. A. Aksoy, C. Klebanoff, J. Hammerbacher, 2019, The Journal of clinical investigation.

Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: selective rescue by caspase inhibition.

S. Rosenberg, T. Zaks, N. Restifo, 1999, Journal of immunology.

Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy.

C. Klebanoff, D. Stroncek, M. Kruhlak, 2017, JCI insight.

Preclinical Evaluation of Chimeric Antigen Receptors Targeting CD70-Expressing Cancers

J. Yang, N. Restifo, Zhiya Yu, 2016, Clinical Cancer Research.

Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy.

F. Marincola, S. Rosenberg, P. Muranski, 2015, The Journal of clinical investigation.

Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells.

S. Rosenberg, N. Restifo, J. Kochenderfer, 2010, Blood.

The power and pitfalls of IL-12.

N. Restifo, S. Kerkar, Sid P. Kerkar, 2012, Blood.

Antigensof Autologous Melanoma Glycoprotein 100 and Does Not Alter the Recognition of Melanoma Tumor Antigen Primary Human Lymphocytes Affords Avid High Efficiency TCR Gene Transfer into

S. Rosenberg, P. Robbins, N. Restifo, 2013 .

regression and targets normal tissues expressing cognate antigen Gene therapy with human and mouse T-cell receptors mediates cancer

S. Rosenberg, Alexandria P. Cogdill, R. Morgan, 2009 .

T-Cell Receptor Gene Therapy of Established Tumors in a Murine Melanoma Model

T. Schumacher, S. Rosenberg, R. Morgan, 2008, Journal of immunotherapy.

Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition

S. Rosenberg, R. Morgan, S. Jones, 2008, Gene Therapy.

High Efficiency TCR Gene Transfer into Primary Human Lymphocytes Affords Avid Recognition of Melanoma Tumor Antigen Glycoprotein 100 and Does Not Alter the Recognition of Autologous Melanoma Antigens

S. Rosenberg, R. Morgan, P. Robbins, 2003, The Journal of Immunology.

and normal B cells antigen receptor that recognizes murine CD19 can eradicate lymphoma Adoptive transfer of syngeneic T cells transduced with a chimeric

S. Rosenberg, N. Restifo, J. Kochenderfer, 2013 .

Type I Interferons are essential for the efficacy of replicase-based DNA vaccines.

E. Bergmann-Leitner, N. Restifo, W. Leitner, 2006, Vaccine.

Genome-wide profiling of druggable active tumor defense mechanisms to enhance cancer immunotherapy

Neville E. Sanjana, N. Sanjana, K. Wood, 2019, bioRxiv.

Generation of Tumor Antigen-Specific iPSC-Derived Thymic Emigrants Using a 3D Thymic Culture System.

Fumito Ito, Benjamin L. Kidder, Chengyu Liu, 2018, Cell reports.

Naive tumor-specific CD4+ T cells differentiated in vivo eradicate established melanoma

P. Muranski, N. Restifo, P. Antony, 2010, The Journal of experimental medicine.

Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen.

S. Rosenberg, Y. Zhai, V. Bronte, 1996, Journal of immunology.

Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment.

S. Rosenberg, R. Morgan, N. Restifo, 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

A nonimmunogenic sarcoma transduced with the cDNA for interferon gamma elicits CD8+ T cells against the wild-type tumor: correlation with antigen presentation capability

S. Rosenberg, J. Mulé, N. Restifo, 1992, The Journal of experimental medicine.

BACH2 immunodeficiency illustrates an association between super-enhancers and haploinsufficiency

J. Hughes, J. McElwee, P. Wingfield, 2017, Nature Immunology.

T cells and IFN-γ. These findings demonstrate that BACH2 is a key component of the molecular program of tumor immunosuppression and identify therapeutic targets for the reversal of immunosuppression in cancer. The transcription factor BACH2 promotes tumor immunosuppression

F. Marincola, K. Okkenhaug, Jenny H. Pan, 2016 .

The transcription factor BACH2 promotes tumor immunosuppression.

F. Marincola, K. Okkenhaug, Jenny H. Pan, 2016, The Journal of clinical investigation.

Polymeric Structure and Host Toll-like Receptor 4 Dictate Immunogenicity of NY-ESO-1 Antigen in Vivo*

G. Cheng, G. Zeng, N. Restifo, 2011, The Journal of Biological Chemistry.

Metabolic reprograming of anti-tumor immunity.

N. Restifo, Madhusudhanan Sukumar, R. Kishton, 2017, Current opinion in immunology.

Glucocorticoids Do Not Inhibit Antitumor Activity of Activated CD8+ T Cells

S. Rosenberg, N. Restifo, D. Palmer, 2005, Journal of immunotherapy.

Adoptive T cell therapy of cancer.

T. Schumacher, N. Restifo, 2009, Current opinion in immunology.

Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers.

S. Rosenberg, P. Muranski, N. Restifo, 2008, Blood.

Flu: The Story of the Great Influenza Pandemic of 1918 and the Search for the Virus that Caused It

N. Restifo, 2000, Nature Medicine.

De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model.

K. Irvine, Julie A Hong, D. Schrump, 2006, Cancer research.

Host conditioning with IL-1β improves the antitumor function of adoptively transferred T cells

R. Germain, W. Paul, N. Restifo, 2019, The Journal of experimental medicine.

obviates the requirement for in vivo vaccination T cells in vitro + Programming tumor-reactive effector memory CD8

C. Klebanoff, N. Restifo, L. Gattinoni, 2013 .

Programming tumor-reactive effector memory CD8+ T cells in vitro obviates the requirement for in vivo vaccination.

C. Klebanoff, N. Restifo, L. Gattinoni, 2009, Blood.

Enhanced efficacy and limited systemic cytokine exposure with membrane-anchored interleukin-12 T-cell therapy in murine tumor models

S. Rosenberg, R. Morgan, N. Restifo, 2020, Journal for ImmunoTherapy of Cancer.

Constitutive Lck Activity Drives Sensitivity Differences between CD8+ Memory T Cell Subsets

I. Osman, N. Varadarajan, A. Frey, 2016, The Journal of Immunology.

Pharmacologic Induction of CD8+ T Cell Memory: Better Living Through Chemistry

C. Klebanoff, N. Restifo, L. Gattinoni, 2009, Science Translational Medicine.

Can antitumor immunity help to explain "oncogene addiction"?

N. Restifo, 2010, Cancer cell.

Mouse Model for Pre‐Clinical Study of Human Cancer Immunotherapy

N. Restifo, W. Overwijk, Y. Hailemichael, 2015, Current protocols in immunology.

Ubiquitously while Mediating Specific Tumor CD8+ T Cells Traffic Indiscriminately and Vaccine-Stimulated, Adoptively Transferred

N. Restifo, L. Gattinoni, D. Palmer, 2013 .

Nine lives for TH9s?

W. Zou, N. Restifo, 2012, Nature Medicine.

Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in mice

M. Smyth, P. Darcy, N. Restifo, 2011, Cancer Immunology, Immunotherapy.

Cancer immunotherapy.

S. Rosenberg, N. Restifo, M. Dudley, 2008, The New England journal of medicine.

with Melanoma'' T Cells in Patients + Antigen-Specific CD8 of Very High Levels of Self/Tumor Progression Can Occur despite the Induction Response to Comment on ''Tumor

S. Rosenberg, N. Restifo, 2006 .

The in vivo expansion rate of properly stimulated transferred CD8+ T cells exceeds that of an aggressively growing mouse tumor.

N. Restifo, D. Palmer, Zhiya Yu, 2006, Cancer research.

Interleukin-7-dependent expansion and persistence of melanoma-specific T cells in lymphodepleted mice lead to tumor regression and editing.

B. Fox, W. Urba, N. Restifo, 2005, Cancer research.

Less is more: lymphodepletion followed by hematopoietic stem cell transplant augments adoptive T-cell-based anti-tumor immunotherapy.

N. Restifo, Claudia Wrzesinski, 2005, Current opinion in immunology.

Dendritic Cells Strongly Boost the Antitumor Activity of Adoptively Transferred T Cells In vivo

P. Hwu, G. Lizée, Y. Lou, 2004, Cancer Research.

Destruction TumorUbiquitously while Mediating Specific T Cells Traffic Indiscriminately and + CD 8 Vaccine-Stimulated , Adoptively Transferred

C. Klebanoff, J. Yang, N. Restifo, 2004 .

Next generation immunotherapy: enhancing stemness of polyclonal T cells to improve anti-tumor activity.

N. Restifo, S. Vodnala, R. Kishton, 2021, Current opinion in immunology.

Identifying the source of tumour-infiltrating T cells

N. Restifo, Suman Kumar Vodnala, 2019, Nature.

Targeting Akt in cell transfer immunotherapy for cancer

N. Restifo, Madhusudhanan Sukumar, Joseph G. Crompton, 2016, Oncoimmunology.

T helper 17 cells promote cytotoxic T cell activation in tumor immunity.

P. Hwu, P. Muranski, N. Restifo, 2009, Immunity.

Cancer Therapy : Preclinical Determinants of Successful CD 8 þ T-Cell Adoptive Immunotherapy for Large Established Tumors in Mice

S. Rosenberg, P. Muranski, C. Klebanoff, 2011 .

Retinoic acid controls the homeostasis of pre-cDC–derived splenic and intestinal dendritic cells

Y. Belkaid, R. Danner, P. Muranski, 2013, The Journal of experimental medicine.

Targeting Tyrosinase Engineered with a Highly Avid TCR Effective In Vivo Tumor Treatment When Both CD4 and CD8 T Cells Mediate Equally

Zhili, W. Burns, J. Wargo, 2010 .

Both CD4 and CD8 T Cells Mediate Equally Effective In Vivo Tumor Treatment When Engineered with a Highly Avid TCR Targeting Tyrosinase

W. Burns, J. Wargo, S. Rosenberg, 2010, The Journal of Immunology.

Erratum: Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling (Journal of Clinical Investigation (2007) 117, (2197-2204) DOI:10.1172/JCI32205)

S. Rosenberg, P. Muranski, N. Restifo, 2007 .

Big bang theory of stem-like T cells confirmed.

N. Restifo, 2014, Blood.

Insideblood ® 2 4 J a N U a R Y 2 0 1 3 I V O L U M E 1 2 1 , N U M B E R 4

N. Restifo, 2013 .

Moving T memory stem cells to the clinic.

N. Restifo, L. Gattinoni, 2013, Blood.

Comment on Stemberger Et Al, Page 628

N. Restifo, 2022 .

Wnt/β-Catenin Signaling in T-Cell Immunity and Cancer Immunotherapy

N. Restifo, L. Gattinoni, Y. Ji, 2010, Clinical Cancer Research.

Reply to: “β-catenin does not regulate memory T cell phenotype”

N. Restifo, L. Gattinoni, Y. Ji, 2010, Nature Medicine.

Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells

S. Rosenberg, C. Klebanoff, N. Restifo, 2005, The Journal of experimental medicine.

RecurrenceAntigen Loss Results in Murine Melanoma Regulatory T Cells and T Cell-Mediated Increased Frequency of Suppressive

B. Fox, N. Restifo, P. Antony, 2012 .

Increased Frequency of Suppressive Regulatory T Cells and T Cell-Mediated Antigen Loss Results in Murine Melanoma Recurrence

B. Fox, N. Restifo, P. Antony, 2012, The Journal of Immunology.

Interleukin-2-dependent mechanisms of tolerance and immunity in vivo

C. Klebanoff, N. Restifo, D. Palmer, 2006, The Journal of Immunology.

Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells.

S. Rosenberg, F. Pericle, V. Bronte, 1998, Journal of immunology.

Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation.

P. Hwu, V. Bronte, N. Restifo, 1999, Journal of immunology.

histocompatibility antigen Immunologic ignorance of vascular endothelial cells expressing minor

D. Engeler, P. Krebs, B. Ludewig, 2013 .

Immunologic ignorance of vascular endothelial cells expressing minor histocompatibility antigen.

D. Engeler, P. Krebs, B. Ludewig, 2008, Blood.

Autoimmunity and the immunotherapy of cancer: targeting the "self" to destroy the "other".

N. Restifo, W. Overwijk, 2000, Critical reviews in immunology.

Cross‐priming utilizes antigen not available to the direct presentation pathway

J. M. Grant, N. Restifo, D. Palmer, 2006, Immunology.

The next wave of recombinant and synthetic anticancer vaccines.

K. Irvine, N. Restifo, 1995, Seminars in cancer biology.

Minimal determinant expressed by a recombinant vaccinia virus elicits therapeutic antitumor cytolytic T lymphocyte responses.

S. Rosenberg, M. Nishimura, K. Irvine, 1995, Cancer research.

Cancer vaccines: progress reveals new complexities.

N. Restifo, Zhiya Yu, 2002, The Journal of clinical investigation.

B16 as a Mouse Model for Human Melanoma

N. Restifo, W. Overwijk, 2000, Current protocols in immunology.

Self-Tolerance to the Murine Homologue of a Tyrosinase-Derived Melanoma Antigen

V. Engelhard, R. Pierce, C. J. Luckey, 2000, The Journal of experimental medicine.

Developing recombinant and synthetic vaccines for the treatment of melanoma.

S. Rosenberg, N. Restifo, 1999, Current opinion in oncology.

Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine.

F. Marincola, B. Moss, S. Rosenberg, 1997, Proceedings of the National Academy of Sciences of the United States of America.

IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression.

B. Moss, S. Rosenberg, K. Irvine, 1996, Journal of immunology.

Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases.

S. Rosenberg, K. Irvine, N. Restifo, 1996, Journal of immunology.

Anti‐Tumor Activity of Cytotoxic T Lymphocytes Elicited with Recombinant and Synthetic Forms of a Model Tumor‐Associated Antigen

S. Rosenberg, V. Bronte, N. Restifo, 1995, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen.

S. Rosenberg, L. Gritz, V. Bronte, 1995, Journal of immunology.

IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases.

S. Rosenberg, V. Bronte, N. Restifo, 1995, Journal of immunology.

Synthetic oligonucleotide expressed by a recombinant vaccinia virus elicits therapeutic CTL.

S. Rosenberg, K. Irvine, N. Restifo, 1995, Journal of immunology.

Ribosomal Proteins Regul ate MHC Class I Peptide Generation for Immunosurveillance Graphical

L. Staudt, J. Yewdell, Jiajie Wei, 2019 .

Molecular mechanisms used by tumors to escape immune recognition: immunogenetherapy and the cell biology of major histocompatibility complex class I.

F. Marincola, S. Rosenberg, N. Restifo, 1993, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

IDENTIFICATION OF HUMAN CANCERS DEFECTIVE IN ANTIGEN PROCESSING

J. Yewdell, J. Bennink, S. Rosenberg, 1993 .

Viruses Encoding the Anchor-modified gp 100 Melanoma Antigen Can Generate Antitumor Immune Responses in Patients with Metastatic Melanoma

S. Rosenberg, P. Hwu, J. Yang, 2003 .

Transgenic Mice Human gp100 Epitope Using DR4-IE Identification of a MHC Class II-Restricted

P. Robbins, N. Restifo, W. Leitner, 2000 .

Defective presentation of endogenous antigens by a murine sarcoma. Implications for the failure of an anti-tumor immune response.

A. Asher, J. Yewdell, J. Bennink, 1991, Journal of immunology.

Intensity of the Vaccine-Elicited Immune Response Determines Tumor Clearance

F. Marincola, P. Matzinger, N. Restifo, 2002, The Journal of Immunology.

Cytokine secretion by genetically modified nonimmunogenic murine fibrosarcoma. Tumor inhibition by IL-2 but not tumor necrosis factor.

A. Asher, S. Rosenberg, P. Hwu, 1993, Journal of immunology.

Murine tumor cells transduced with the gene for tumor necrosis factor-alpha. Evidence for paracrine immune effects of tumor necrosis factor against tumors.

A. Asher, S. Rosenberg, J. Mulé, 1991, Journal of immunology.

Normal Tissue Depresses While Tumor Tissue Enhances Human T Cell Responses In Vivo to a Novel Self/Tumor Melanoma Antigen, OA1

A. Sette, S. Rosenberg, R. Schnur, 2003, The Journal of Immunology.

Antigen , OA 1 Vivo to a Novel Self / Tumor Melanoma Tissue Enhances Human T Cell Responses In Normal Tissue Depresses While Tumor

A. Sette, S. Rosenberg, R. Schnur, 2003 .

Do CD4+ CD25+ immunoregulatory T cells hinder tumor immunotherapy?

N. Restifo, P. Antony, 2002, Journal of immunotherapy.

Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts

Michael F. Sharpnack, D. Schadendorf, R. Sullivan, 2018, Journal of Translational Medicine.

Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity

G. Nabel, Andreas Radbruch, S. Kochanek, 2010, Nature Medicine.

and Induces Protective Immunity to Infectious and Humoral and Cellular Immune Responses CD40 Ligand/Trimer DNA Enhances Both

K. Irvine, S. Gurunathan, R. Seder, 2013 .

CD40 ligand/trimer DNA enhances both humoral and cellular immune responses and induces protective immunity to infectious and tumor challenge.

K. Irvine, S. Gurunathan, R. Seder, 1998, Journal of immunology.

Tumor Challenge andInduces Protective Immunity to Infectious andHumoral and Cellular Immune Responses CD 40 Ligand / Trimer DNA Enhances Both

K. Irvine, S. Gurunathan, J. Cohen, 1998 .

Mining the melanosome for tumor vaccine targets: P.polypeptide is a novel tumor-associated antigen.

S. Rosenberg, P. Robbins, N. Restifo, 2001, Cancer research.

Maturation Dysregulating Antigen-Presenting Cell T Cell Responses by + Inhibits CD 8 Colony-Stimulating Factor by Tumors Granulocyte-Macrophage Unopposed Production

P. Hwu, V. Bronte, N. Restifo, 1999 .

Selective Rescue by Caspase Inhibition Tumor : Cells Following Activation by Specific Fas-Mediated Suicide of Tumor-Reactive T

S. Rosenberg, T. Zaks, N. Restifo, 1999 .

Suppressive Population of Mac-1 After Immunization : Induction of a T Lymphocytes + Apoptotic Death of CD 8 and

S. Rosenberg, F. Pericle, V. Bronte, 1998 .

T cell–tumor cell: a fatal interaction?

N. Restifo, D. Chappell, 1998, Cancer Immunology, Immunotherapy.

Identification of a CD 11 b 1 / Gr-1 1 / CD 31 1 myeloid progenitor capable of activating or suppressing CD 8 1 T cells

R. Ronca, V. Bronte, N. Restifo, 2000 .

Transfectant influenza A viruses are effective recombinant immunogens in the treatment of experimental cancer.

S. Rosenberg, A. García-Sastre, P. Palese, 1998, Virology.

Erratum: TH 17 cells in tumour immunity and immunotherapy (Nature Reviews Immunology (2010) 10 (248-256))

W. Zou, N. Restifo, 2011 .

TH17 cells in tumour immunity and immunotherapy

W. Zou, N. Restifo, 2011, Nature Reviews Immunology.

Peptide / MHC Complex : Implications for Is Due to the Enhanced Stability of the Anchor-Modified Tumor-Associated Antigen Increased Immunogenicity of an

B. Baker, N. Restifo, Zhiya Yu, 2005 .

Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes.

S. Rosenberg, S. Topalian, A. Mixon, 1995, Cancer research.

DNA and RNA-based vaccines: principles, progress and prospects.

N. Restifo, W. Leitner, H. Ying, 1999, Vaccine.

The new vaccines: building viruses that elicit antitumor immunity.

N. Restifo, 1996, Current opinion in immunology.

Interleukin-10 enhances the therapeutic effectiveness of a recombinant poxvirus-based vaccine in an experimental murine tumor model.

S. Rosenberg, K. Irvine, H. Kaufman, 1999, Journal of immunotherapy.

THE USE OF RECOMBINANT POXVIRUSES AS A PARADIGM FOR THE DEVELOPMENT OF ANTI-CANCER VACCINES

K. Irvine, N. Restifo, R. Chamberlain, 1998 .

Enhanced T-cell activation and differentiation in lymphocytes from transgenic mice expressing ubiquitination-resistant 2KR LAT molecules

Y. Belkaid, L. Samelson, R. Kortum, 2015, Gene Therapy.

Human melanoma cells do not express Fas (Apo-1/CD95) ligand.

S. Rosenberg, T. Zaks, N. Restifo, 1999, Cancer research.

Route of immunization and the therapeutic impact of recombinant anticancer vaccines.

S. Rosenberg, K. Irvine, E. P. Shulman, 1997, Journal of the National Cancer Institute.

Cancer Vaccines '98: a reductionistic approach

N. Restifo, 1998 .

High-avidity Autoreactive CD4+ T Cells Induce Host CTL, Overcome Tregs and Mediate Tumor Destruction

J. Sidney, N. Restifo, W. Leitner, 2009, Journal of immunotherapy.

Expression of a "self-"antigen by human tumor cells enhances tumor antigen-specific CD4(+) T-cell function.

S. Rosenberg, P. Hwu, P. Robbins, 2002, Cancer research.

The future of interleukin-2: enhancing therapeutic anticancer vaccines.

N. Restifo, M. Theoret, W. Overwijk, 2000, The cancer journal from Scientific American.

Construction and characterization of a triple-recombinant vaccinia virus encoding B7-1, interleukin 12, and a model tumor antigen.

B. Moss, M. Carroll, N. Restifo, 1998, Journal of the National Cancer Institute.

Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines.

B. Moss, S. Rosenberg, P. Hwu, 1996, Cancer research.

Strength in Numbers: Identifying Neoantigen Targets for Cancer Immunotherapy

Rachel C. Lynn, N. Restifo, R. Kishton, 2020, Cell.

Using Human Induced Pluripotent Stem Cells for the Generation of Tumor Antigen-specific T Cells.

T. Maeda, H. Kawamoto, N. Restifo, 2019, Journal of visualized experiments : JoVE.

The Cish SH2 domain is essential for PLC-γ1 regulation in TCR stimulated CD8+ T cells

V. Barr, Ana Dios-Esponera, L. Samelson, 2018, Scientific Reports.

Enhancement of tumor-specific immune response with plasmid DNA replicon vectors.

T. Dubensky, D. Driver, N. Restifo, 2000, Cancer research.

Generation of polyclonal rabbit antisera to mouse melanoma associated antigens using gene gun immunization.

S. Rosenberg, K. Irvine, E. P. Shulman, 1998, Journal of immunological methods.

Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100.

S. Rosenberg, M. Nishimura, Y. Zhai, 1997, Journal of immunotherapy.

Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates.

B. Moss, J. Bennink, J. Lifson, 1996, Advances in experimental medicine and biology.

Locus-specific analysis of human leukocyte antigen class I expression in melanoma cell lines.

F. Marincola, J. Mulé, P. Fetsch, 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Genetic vaccination with "self" tyrosinase-related protein 2 causes melanoma eradication but not vitiligo.

R. Ronca, V. Bronte, N. Restifo, 2000, Cancer research.

T-cell recognition of human melanoma antigens.

S. Rosenberg, M. Nishimura, S. Topalian, 1993, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Detection of shared MHC-restricted human melanoma antigens after vaccinia virus-mediated transduction of genes coding for HLA.

J. Yewdell, J. Bennink, S. Rosenberg, 1993, Journal of immunology.

Recognition of neuroectodermal tumors by melanoma-specific cytotoxic T lymphocytes: evidence for antigen sharing by tumors derived from the neural crest

S. Rosenberg, S. Topalian, N. Restifo, 1994, Cancer Immunology, Immunotherapy.

IFN‐γ‐receptor signaling ameliorates transplant vasculopathy through attenuation of CD8+ T‐cell‐mediated injury of vascular endothelial cells

D. Engeler, P. Krebs, B. Ludewig, 2010, European journal of immunology.

Enhancing the recognition of tumor associated antigens

K. Irvine, N. Restifo, B. Minev, 2009 .

Genetic Engineering of Murine CD8+ and CD4+ T Cells for Preclinical Adoptive Immunotherapy Studies

S. Rosenberg, P. Muranski, C. Klebanoff, 2011, Journal of immunotherapy.

Cancer genes disfavoring T cell immunity identified via integrated systems approach

Roxana A. Stefanescu, Neville E. Sanjana, N. Sanjana, 2022, Cell reports.

Fine-tuning T cell function through engineered orthogonal chimeric cytokine receptors

N. Restifo, R. Kishton, 2022, Cell Research.

5-AZA-2′-Deoxycytidine in Cancer Immunotherapy: A Mouse to Man Story

D. Schrump, Z. Guo, N. Restifo, 2007 .

Arginine Arms T Cells to Thrive and Survive.

N. Restifo, Madhusudhanan Sukumar, R. Kishton, 2016, Cell metabolism.

Induction of CD4(+) T cell-dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cells.

P. Hwu, J. Yang, Helen Y Wang, 2002, The Journal of clinical investigation.

Antiangiogenic gene therapy of cancer utilizing a recombinant adenovirus to elevate systemic endostatin levels in mice.

A. Feldman, S. Libutti, P. Hwu, 2000, Cancer research.

Self-organized yolk sac-like organoids allow for scalable generation of multipotent hematopoietic progenitor cells from induced pluripotent stem cells

D. Goldstein, M. Kimura, T. Takebe, 2021, bioRxiv.

Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance

F. Marincola, C. Klebanoff, E. Wang, 2015, Journal for ImmunoTherapy of Cancer.

Procédés de production de populations de lymphocytes t à l'aide d'inhibiteurs d'akt

N. Restifo, Joseph G. Crompton, Joseph G Crompton, 2016 .

Vaccines to die for

N. Restifo, 2001, Nature Biotechnology.

Causes Melanoma Eradication but not Vitiligo Genetic Vaccination with ''Self'' Tyrosinase-related Protein 2

R. Ronca, V. Bronte, N. Restifo, 2000 .

Recombinant virus vaccination against "self" antigens using anchor-fixed immunogens.

R. Offringa, S. Rosenberg, K. Irvine, 1999, Cancer research.

immunization with a recombinant adenovirus Therapeutic antitumor response after

S. Rosenberg, Y. Zhai, V. Bronte, 2001 .

a Peptide Vaccine Patients with Metastatic Melanoma Receiving Generation of Antitumor Reactivity in Impact of Cytokine Administration on the

F. Marincola, S. Rosenberg, P. Hwu, 1999 .

The Role of Glycogen Synthase Kinase 3 in Regulating IFN-b–Mediated IL-10 Production

Carlos A. Garcia, J. Wargo, S. Rosenberg, 2010 .

Chemokine receptor targeting efﬁciently directs antigens to MHC class I pathways and elicits antigen-speciﬁc CD8 (cid:1) T-cell responses

D. Taub, R. Schiavo, N. Restifo, 2006 .

Advances in Brief Expression of a “ Self-” Antigen by Human Tumor Cells Enhances Tumor Antigen-specific CD 4 T-Cell Function

S. Rosenberg, P. Hwu, P. Robbins, 2002 .

MHC class I and class II presentation of tumor antigen in retrovirally and adenovirally transduced dendritic cells

P. Hwu, P. Robbins, N. Restifo, 2002, Cancer Gene Therapy.

Countering the 'counterattack' hypothesis

N. Restifo, 2001, Nature Medicine.

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.

S. Rosenberg, J. Yang, S. Topalian, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Conventional Endosomes and Is Influenced in Melanoma Cells Requires the Function of MHC Class II Presentation of gp100 Epitopes

M. Marks, A. Theos, N. Restifo, 2017 .

MHC Class II Presentation of gp100 Epitopes in Melanoma Cells Requires the Function of Conventional Endosomes and Is Influenced by Melanosomes1

V. Engelhard, M. Marks, A. Theos, 2008, The Journal of Immunology.

Mitochondrial activity regulates T cell memory, self renewal and anti tumor function in CD8+ T cells

Mahadev Rao, T. Finkel, N. Restifo, 2013, Journal of Immunotherapy for Cancer.

Tumor Regression and Autoimmunity after Reversal of a Functionally Tolerant State of Self-reactive CD8+ T Cells

S. Rosenberg, C. Klebanoff, N. Restifo, 2003, The Journal of experimental medicine.

Mg 2+ regulation of kinase signaling and immune function

M. Lenardo, J. Cannons, P. Schwartzberg, 2019 .

Definitive hematopoietic stem/progenitor cells from human embryonic stem cells through serum/feeder-free organoid-induced differentiation

K. Keyvanfar, D. Malide, J. Tisdale, 2020, Stem Cell Research & Therapy.

Dose-dependent and schedule-dependent effects of interleukin-12 on antigen-specific CD8 responses.

A. Dorner, N. Restifo, W. Overwijk, 2000, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

gp100/pmel 17 Is a Murine Tumor Rejection Antigen: Induction of “Self”-reactive, Tumoricidal T Cells Using High-affinity, Altered Peptide Ligand

B. Moss, S. Rosenberg, K. Irvine, 1998, The Journal of experimental medicine.

Hierarchy, Tolerance, and Dominance in the Antitumor T-Cell Response.

N. Restifo, 2001, Journal of immunotherapy : official journal of the Society for Biological Therapy.

Identification of human cancers deficient in antigen processing

J. Yewdell, J. Bennink, S. Rosenberg, 1993, The Journal of experimental medicine.

Cancer therapy using a self-replicating RNA vaccine

F. Marincola, K. Irvine, T. Zaks, 1999, Nature Medicine.

In vivo activity of tumor necrosis factor (TNF) mutants. Secretory but not membrane-bound TNF mediates the regression of retrovirally transduced murine tumor.

S. Rosenberg, P. Hwu, J. Mulé, 1992, Journal of immunology.

Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68

F. Marincola, P. Ascierto, D. Bedognetti, 2011, BMC Cancer.

Adoptive immunotherapy for cancer: building on success

S. Rosenberg, D. Powell, N. Restifo, 2006, Nature Reviews Immunology.

Human memory T cells: generation, compartmentalization and homeostasis

D. Farber, N. Restifo, Nicholas P. Restifo, 2013, Nature Reviews Immunology.

Increased intensity lymphodepletion and adoptive immunotherapy—how far can we go?

S. Rosenberg, D. Citrin, P. Muranski, 2006, Nature Clinical Practice Oncology.

The Bone Marrow Protects and Optimizes Immunological Memory during Dietary Restriction

Y. Belkaid, P. Schwartzberg, Nicholas Collins, 2019, Cell.

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

Thomas A. Davis, Steven A. Rosenberg, Douglas J. Schwartzentruber, 2003, Proceedings of the National Academy of Sciences of the United States of America.

The promise of nucleic acid vaccines

N. Restifo, W. Leitner, L. Hwang, 2000, Gene Therapy.

Mg2+ regulation of kinase signaling and immune function

M. Lenardo, J. Cannons, P. Schwartzberg, 2019, The Journal of experimental medicine.

Chemokine receptor targeting efficiently directs antigens to MHC class I pathways and elicits antigen-specific CD8+ T-cell responses.

D. Taub, R. Schiavo, N. Restifo, 2006, Blood.

Tumor-specific CD4+ T cells maintain effector and memory tumor-specific CD8+ T cells

B. Fox, N. Restifo, P. Antony, 2013, European journal of immunology.

TH17 cells in tumour immunity and immunotherapy

W. Zou, N. Restifo, 2010, Nature Reviews Immunology.

Novel “Elements” of Immune Suppression within the Tumor Microenvironment

N. Restifo, R. Eil, D. Clever, 2017, Cancer Immunology Research.

Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma.

John Mao, Francesco M Marincola, F. Marincola, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Transplantation of mouse HSCs genetically modified to express a CD4-restricted TCR results in long-term immunity that destroys tumors and initiates spontaneous autoimmunity.

K. Cornetta, H. Broxmeyer, G. Hangoc, 2010, The Journal of clinical investigation.

GILT Accelerates Autoimmunity to the Melanoma Antigen Tyrosinase-Related Protein 1

P. Cresswell, K. Irvine, N. Restifo, 2010, The Journal of Immunology.

Developing neoantigen-targeted T cell–based treatments for solid tumors

N. Restifo, Tori N. Yamamoto, R. Kishton, 2019, Nature Medicine.

Bach2 represses effector programmes to stabilize Treg-mediated immune homeostasis

F. Marincola, D. Bedognetti, B. Dema, 2013, Nature.

Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma.

S. Rosenberg, W. Wong, R. Nussenblatt, 2009, Ophthalmology.

Multimodel preclinical platform predicts clinical response of melanoma to immunotherapy

Chi-Ping Day, Glenn Merlino, Shyam K. Sharan, 2020, Nature Medicine.

A cleavage product of Polycystin-1 is a mitochondrial matrix protein that affects mitochondria morphology and function when heterologously expressed

Yi Liu, G. Germino, W. Prinz, 2018, Scientific Reports.

A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response

Sadik H. Kassim, M. Raffeld, S. Rosenberg, 2014, Clinical Cancer Research.

Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor–transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma

H. Fine, M. Raffeld, S. Rosenberg, 2019, Journal of immunotherapy.

Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting

D. Tscharke, J. Trapani, S. Rosenberg, 2016, Clinical Cancer Research.

Double or nothing on cancer immunotherapy

N. Restifo, K. Hanada, 2013, Nature Biotechnology.

Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors

J. Yang, N. Restifo, Zhiya Yu, 2015, Cancer Immunology Research.

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.

S. Rosenberg, Alexandria P. Cogdill, R. Morgan, 2009, Blood.

Simultaneous targeting of tumor antigens and the tumor vasculature using T lymphocyte transfer synergize to induce regression of established tumors in mice.

S. Rosenberg, R. Morgan, E. Tran, 2013, Cancer research.

Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice.

S. Rosenberg, R. Morgan, N. Restifo, 2010, The Journal of clinical investigation.

Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model.

S. Rosenberg, N. Restifo, Christian S. Hinrichs, 2018, JCI insight.

IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T Cells

T. Waldmann, S. Rosenberg, C. Klebanoff, 2004, Proceedings of the National Academy of Sciences of the United States of America.

T cell stemness and dysfunction in tumors are triggered by a common mechanism

J. Locasale, C. Klebanoff, Jing Huang, 2019, Science.

IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors.

F. Marincola, G. Trinchieri, R. Goldszmid, 2011, The Journal of clinical investigation.

Defective major histocompatibility complex class I expression in a sarcomatoid renal cell carcinoma cell line.

F. Marincola, W. Linehan, S. Rosenberg, 1995, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Inhibition of TGF-β signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy

S. Rosenberg, P. Muranski, R. Morgan, 2012, Gene Therapy.

Paths to stemness: building the ultimate antitumour T cell

C. Klebanoff, N. Restifo, L. Gattinoni, 2012, Nature Reviews Cancer.

Antigen‐specific tumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHC

M. Sanda, K. McDonagh, N. Restifo, 2002, The Prostate.

Antigen-SpecificTumorVaccine Efficacy InVivo Against ProstateCancerwith LowClass IMHC

M. Sanda, K. McDonagh, N. Restifo, 2002 .

The interplay of effector and regulatory T cells in cancer.

N. Restifo, R. Roychoudhuri, R. Eil, 2015, Current opinion in immunology.

Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics.

Mark S. Sundrud, F. Marincola, S. Rosenberg, 2015, Cancer research.

Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens.

F. Marincola, S. Rosenberg, P. Hwu, 1998, Journal of the National Cancer Institute.

Stretch-Enhancers Delineate Disease-Associated Regulatory Nodes in T Cells

Stephen C. J. Parker, Yuka Kanno, Yijun Ruan, 2014, Nature.

Regulation of nucleosome landscape and transcription factor targeting at tissue-specific enhancers by BRG1.

Keji Zhao, Dustin E. Schones, Kairong Cui, 2011, Genome research.

Suppressors of cytokine signaling (SOCS) in T cell differentiation, maturation, and function.

N. Restifo, D. Palmer, 2009, Trends in immunology.

Elucidating the Autoimmune and Antitumor Effector Mechanisms of a Treatment Based on Cytotoxic T Lymphocyte Antigen-4 Blockade in Combination with a B16 Melanoma Vaccine

R. Offringa, C. Melief, J. Allison, 2001, The Journal of experimental medicine.

ASXL3 Is a Novel Pluripotency Factor in Human Respiratory Epithelial Cells and a Potential Therapeutic Target in Small Cell Lung Cancer.

S. Davis, Yonghong Wang, T. Ried, 2017, Cancer research.

Epigenetic control of CD8+ T cell differentiation

N. Restifo, R. Roychoudhuri, A. Henning, 2018, Nature Reviews Immunology.

BACH2 regulates CD8+ T cell differentiation by controlling access of AP-1 factors to enhancers

Yuka Kanno, Yun Ji, Yoshiyuki Wakabayashi, 2016, Nature Immunology.

Identification of Small Molecule Enhancers of Immunotherapy for Melanoma

M. Ferrer, Noel Southall, A. Jadhav, 2020, Scientific Reports.

Internal checkpoint regulates T cell neoantigen reactivity and susceptibility to PD1 blockade

Natalie K. Wolf, Walker S. Lahr, Beau R. Webber, 2020, bioRxiv.

Multi-model preclinical platform predicts clinical response of melanoma to immunotherapy

Chi-Ping Day, Glenn Merlino, Shyam K. Sharan, 2019, bioRxiv.

Adoptive immunotherapy of cancer using CD4(+) T cells.

P. Muranski, N. Restifo, 2009, Current opinion in immunology.

Tumor-specific Th17-polarized cells eradicate large established melanoma.

P. Muranski, K. Irvine, N. Restifo, 2008, Blood.

Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy.

N. Restifo, Madhusudhanan Sukumar, R. Kishton, 2017, Cell metabolism.

An effective mouse model for adoptive cancer immunotherapy targeting neoantigens.

N. Restifo, Zhiya Yu, K. Hanada, 2019, JCI insight.

Reprogramming antitumor immunity.

M. Rao, N. Restifo, Joseph G. Crompton, 2014, Trends in immunology.

TEFF TEM TCM TSCM B cell Plasma cell MCPH

M. Rao, N. Restifo, Joseph G. Crompton, 2014 .

Th17 cells are long lived and retain a stem cell-like molecular signature.

S. Kern, R. Danner, P. Muranski, 2011, Immunity.

The transcription factor c-Myb regulates CD8+ T cell stemness and antitumor immunity

W. Telford, Wei Zhu, A. Bhandoola, 2018, Nature Immunology.

Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape

N. Restifo, 2000, Nature Medicine.

MicroRNA-155 is required for effector CD8+ T cell responses to virus infection and cancer.

P. Romero, N. Rufer, Thelma M. Escobar, 2013, Immunity.

Reassessing target antigens for adoptive T cell therapy

N. Restifo, Christian S. Hinrichs, Nicholas P. Restifo, 2013, Nature Biotechnology.

Cellular constituents of immune escape within the tumor microenvironment.

N. Restifo, Nicholas P Restifo, S. Kerkar, 2012, Cancer research.

The kinase DYRK1A reciprocally regulates the differentiation of Th17 and regulatory T cells

R. Xavier, M. Schirmer, S. Schreiber, 2015, eLife.

Microbiota Modulation of Myeloid Cells in Cancer Therapy

A. Dzutsev, G. Trinchieri, R. Goldszmid, 2015, Cancer Immunology Research.

The kinase DYRK 1 A reciprocally regulates the differentiation of Th 17 and regulatory T cells

R. Xavier, M. Schirmer, S. Schreiber, 2015 .

Microbiota Modulation of Myeloid Cells in Cancer

A. Dzutsev, G. Trinchieri, R. Goldszmid, 2015 .

Essentials of Th17 cell commitment and plasticity.

P. Muranski, N. Restifo, 2013, Blood.

Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity.

J. Wolchok, M. Perales, A. Houghton, 2006, Cancer research.

Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function

J. Berzofsky, W. Leonard, J. Brady, 2005, The Journal of experimental medicine.

Identification of the Genomic Insertion Site of Pmel-1 TCR α and β Transgenes by Next-Generation Sequencing

E. Stahlberg, Wei Zhu, N. Restifo, 2014, PloS one.

Sorting Through Subsets: Which T-Cell Populations Mediate Highly Effective Adoptive Immunotherapy?

C. Klebanoff, N. Restifo, L. Gattinoni, 2012, Journal of immunotherapy.

Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells.

T. Waldmann, S. Rosenberg, C. Klebanoff, 2005, Proceedings of the National Academy of Sciences of the United States of America.

Antitumor efficacy of tumor-antigen-encoding recombinant poxvirus immunization in Dunning rat prostate cancer: implications for clinical genetic vaccine development

Martin G. Sanda, Blake Roessler, M. Sanda, 2000, World Journal of Urology.

CD8+ T‐cell memory in tumor immunology and immunotherapy

C. Klebanoff, N. Restifo, L. Gattinoni, 2006, Immunological reviews.

Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.

M. Raffeld, S. Rosenberg, R. Morgan, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Collapse of the tumor stroma is triggered by IL-12 induction of Fas.

S. Rosenberg, R. Morgan, N. Restifo, 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma.

Seth M Steinberg, S. Steinberg, S. Rosenberg, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genome-wide Screens Identify Lineage- and Tumor-Specific Genes Modulating MHC-I- and MHC-II-Restricted Immunosurveillance of Human Lymphomas.

Jesse H. Arbuckle, L. Staudt, George W. Wright, 2020, Immunity.

Genome-wide Screens Identify Lineage- and Tumor Specific-Genes Modulating MHC-I and MHC-II Immunosurveillance in Human Lymphomas

Jesse H. Arbuckle, L. Staudt, George W. Wright, 2020, bioRxiv.

Ribosomal Proteins Regulate MHC Class I Peptide Generation for Immunosurveillance.

L. Staudt, J. Yewdell, Jiajie Wei, 2019, Molecular cell.

Assumptions of the tumor 'escape' hypothesis.

N. Restifo, P. Antony, M. Theoret, 2002, Seminars in cancer biology.

Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling.

S. Rosenberg, P. Muranski, N. Restifo, 2007, The Journal of clinical investigation.

Consensus nomenclature for CD 8 T cell phenotypes in cancer

S. H. van der Burg, J. Blay, F. Marincola, 2015 .

Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A.

F. Marincola, S. Rosenberg, J. Cormier, 1997, The cancer journal from Scientific American.

Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells.

S. Rosenberg, J. Yang, N. Restifo, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Therapeutic cancer vaccines: are we there yet?

C. Klebanoff, N. Restifo, Zhiya Yu, 2011, Immunological reviews.

HPV-targeted tumor-infiltrating lymphocytes for cervical cancer.

Richard Sherry, S. Rosenberg, J. Yang, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oxygen Sensing by T Cells Establishes an Immunologically Tolerant Metastatic Niche

Y. Belkaid, A. Goldrath, C. Klebanoff, 2016, Cell.

Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts.

G. Trinchieri, S. Rosenberg, P. Muranski, 2010, Cancer research.

Cancer esearch oenvironment and Immunology or-Specific CD 8 + T Cells Expressing Interleukin-12 R dicate Established Cancers in Lymphodepleted Hosts

G. Trinchieri, S. Rosenberg, P. Muranski, 2010 .

Biopsychosocial characteristics of children who later murder: a prospective study.

N. Restifo, D. O. Lewis, A. Simos, 1985, American Journal of Psychiatry.

Toll-like Receptors in Tumor Immunotherapy

S. Rosenberg, P. Muranski, N. Restifo, 2007, Clinical Cancer Research.

New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer

F. Marincola, J. Heath, S. Rosenberg, 2012, Journal of Translational Medicine.

Silencing stemness in T cell differentiation

C. Klebanoff, N. Restifo, A. Henning, 2018, Science.

Lineage relationship of CD8+ T cell subsets is revealed by progressive changes in the epigenetic landscape

F. Marincola, Manikandan Narayanan, Suresh Cuddapah, 2015, Cellular and Molecular Immunology.

Lineage relationship of effector and memory T cells.

N. Restifo, L. Gattinoni, 2013, Current opinion in immunology.

T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy

S. Rosenberg, I. Osman, Y. Shao, 2013, Proceedings of the National Academy of Sciences.

An engineered IL-2 partial agonist promotes CD8+ T cell stemness

K. Garcia, W. Leonard, Jangsuk Oh, 2021, Nature.

Building better vaccines: how apoptotic cell death can induce inflammation and activate innate and adaptive immunity.

N. Restifo, 2000, Current opinion in immunology.

Primary pulmonary cytotoxic T lymphocytes induced by immunization with a vaccinia virus recombinant expressing influenza A virus nucleoprotein peptide do not protect mice against challenge

B. Murphy, J. Yewdell, J. Bennink, 1994, Journal of virology.

Virus Nucleoprotein Peptide Do Not Protect Mice

J. Yewdell, J. Bennink, N. Restifo, 2022 .

Molecular characterization of defective antigen processing in human prostate cancer.

M. Sanda, J. Simons, D. Pardoll, 1995, Journal of the National Cancer Institute.

Enhanced expression of HLA-A,B,C and inducibility of TAP-1, TAP-2, and HLA-A,B,C by interferon-gamma in a multidrug-resistant small cell lung cancer line.

J. Wharton, N. Restifo, B. Glisson, 1994, Lymphokine and cytokine research.

TSCOT + Thymic Epithelial Cell-Mediated Sensitive CD4 Tolerance by Direct Presentation

G. Anderson, E. Jenkinson, N. Restifo, 2008, PLoS biology.

Distinct Regulation of Th17 and Th1 Cell Differentiation by Glutaminase-Dependent Metabolism

J. Locasale, Pingsheng Wu, J. Rathmell, 2018, Cell.

Superior T memory stem cell persistence supports long-lived T cell memory.

T. Waldmann, J. Brenchley, P. Chattopadhyay, 2013, The Journal of clinical investigation.

Antigen Experienced T Cells from Peripheral Blood Recognize p53 Neoantigens

M. Raffeld, S. Rosenberg, Frank J. Lowery, 2020, Clinical Cancer Research.

Predominant Role for Directly Transfected Dendritic Cells in Antigen Presentation to CD8+ T Cells after Gene Gun Immunization

R. Germain, A. Iwasaki, K. Irvine, 1998, The Journal of experimental medicine.

Retroviral transduction of interferon-γ cDNA into a nonimmunogenic murinefibrosarcoma: generation of T cells in draining lymph nodes capable of treating established parental metastatic tumor

S. Rosenberg, J. Mulé, N. Restifo, 1993, Cancer Immunology, Immunotherapy.

Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness.

Yingdong Zhao, Richard Simon, Paul H Duray, 2002, Cancer research.

Uncoupling T‐cell expansion from effector differentiation in cell‐based immunotherapy

N. Restifo, Madhusudhanan Sukumar, Joseph G Crompton, 2014, Immunological reviews.

Fas/CD95 prevents autoimmunity independently of lipid raft localization and efficient apoptosis induction

J. Lippincott-Schwartz, P. Sengupta, C. Klebanoff, 2016, Nature Communications.

Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways

B. Williams, R. Silverman, N. Restifo, 2003, Nature Medicine.

CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2.

N. Restifo, P. Antony, 2005, Journal of immunotherapy.

CD4CD25 T Regulatory Cells, Immunotherapy of Cancer, and Interleukin-2

N. Restifo, P. Antony, 2005 .

A TCR Targeting the HLA-A*0201–Restricted Epitope of MAGE-A3 Recognizes Multiple Epitopes of the MAGE-A Antigen Superfamily in Several Types of Cancer

J. Wargo, S. Rosenberg, R. Morgan, 2011, The Journal of Immunology.

Bedside to bench and back again: how animal models are guiding the development of new immunotherapies for cancer

S. Rosenberg, C. Klebanoff, N. Restifo, 2004, Journal of leukocyte biology.

Creating therapeutic cancer vaccines: notes from the battlefield.

N. Restifo, W. Overwijk, W W Overwijk, 2001, Trends in immunology.

High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation.

S. Rosenberg, R. Morgan, N. Restifo, 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy.

C. Klebanoff, N. Restifo, D. Palmer, 2005, Trends in immunology.

Adoptively transferred effector cells derived from naïve rather than central memory CD8+ T cells mediate superior antitumor immunity

Yun Ji, Luis Sanchez-Perez, Douglas C. Palmer, 2009, Proceedings of the National Academy of Sciences.

In vitro generated anti-tumor T lymphocytes exhibit distinct subsets mimicking in vivo antigen-experienced cells

S. Rosenberg, R. Morgan, N. Restifo, 2011, Cancer Immunology, Immunotherapy.

melanoma Tumor-specific Th17-polarized cells eradicate large established

K. Irvine, N. Restifo, L. Gattinoni, 2011 .

Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer.

S. Rosenberg, N. Restifo, M. Theoret, 2010, Cancer research.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

Type I Cytokines Synergize with Oncogene Inhibition to Induce Tumor Growth Arrest

James J. Morrow, F. Marincola, M. Raffeld, 2014, Cancer Immunology Research.

targeting at tissue-specific enhancers by BRG 1 Regulation of nucleosome landscape and transcription factor Material Supplemental

Dustin E. Schones, Kairong Cui, K. Zhao, 2011 .

Immune Selection of Hot-Spot β2-Microglobulin Gene Mutations, HLA-A2 Allospecificity Loss, and Antigen-Processing Machinery Component Down-Regulation in Melanoma Cells Derived from Recurrent Metastases following Immunotherapy1

S. Ferrone, N. Restifo, M. Campoli, 2005, The Journal of Immunology.

Modulating the differentiation status of ex vivo-cultured anti-tumor T cells using cytokine cocktails

S. Rosenberg, R. Morgan, N. Restifo, 2013, Cancer Immunology, Immunotherapy.

Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma

Sadik H. Kassim, S. Rosenberg, R. Morgan, 2015, Clinical Cancer Research.

Mitochondrial Membrane Potential Identifies Cells with Enhanced Stemness for Cellular Therapy.

F. Marincola, W. Leonard, P. Muranski, 2016, Cell metabolism.

Nutrient Competition: A New Axis of Tumor Immunosuppression

N. Restifo, Madhusudhanan Sukumar, R. Roychoudhuri, 2015, Cell.

Cutting Edge: CD4+ T Cell Control of CD8+ T Cell Reactivity to a Model Tumor Antigen

N. Restifo, M. Dudley, D. Surman, 2000, The Journal of Immunology.

CD8+ T Cell Immunity Against a Tumor/Self-Antigen Is Augmented by CD4+ T Helper Cells and Hindered by Naturally Occurring T Regulatory Cells

S. Rosenberg, C. Klebanoff, C. Piccirillo, 2005, The Journal of Immunology.

Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy.

W. Burns, S. Rosenberg, P. Muranski, 2011, Blood.

Increased Immunogenicity of an Anchor-Modified Tumor-Associated Antigen Is Due to the Enhanced Stability of the Peptide/MHC Complex: Implications for Vaccine Design1

B. Baker, N. Restifo, Zhiya Yu, 2005, The Journal of Immunology.

Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia

S. Rosenberg, R. Morgan, E. Tran, 2013, The Journal of experimental medicine.

Treatment of Metastatic Melanoma Using Interleukin-2 Alone or in Conjunction with Vaccines

S. Steinberg, S. Rosenberg, J. Yang, 2008, Clinical Cancer Research.

Clinical Scale Zinc Finger Nuclease-mediated Gene Editing of PD-1 in Tumor Infiltrating Lymphocytes for the Treatment of Metastatic Melanoma.

S. Rosenberg, R. Morgan, David E. Paschon, 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

miR-155 augments CD8+ T-cell antitumor activity in lymphoreplete hosts by enhancing responsiveness to homeostatic γc cytokines

T. Waldmann, W. Telford, C. Klebanoff, 2014, Proceedings of the National Academy of Sciences.

Evaluation of Prime/Boost Regimens Using Recombinant Poxvirus/Tyrosinase Vaccines for the Treatment of Patients with Metastatic Melanoma

S. Steinberg, S. Rosenberg, M. Gonzales, 2006, Clinical Cancer Research.

Identification of a MHC Class II-Restricted Human gp100 Epitope Using DR4-IE Transgenic Mice

Steven A. Rosenberg, S. Rosenberg, S. Topalian, 2000, The Journal of Immunology.

Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine.

F. Marincola, S. Rosenberg, P. Hwu, 1999, Journal of immunology.

Natural variation of the expression of HLA and endogenous antigen modulates CTL recognition in an In vitro melanoma model

F. Marincola, S. Ferrone, A. Mixon, 1999, International journal of cancer.

Treatment of established lung metastases with tumor-infiltrating lymphocytes derived from a poorly immunogenic tumor engineered to secrete human TNF-alpha.

F. Marincola, S. Rosenberg, J. Mulé, 1994, Journal of immunology.

Enhancing the recognition of tumour associated antigens.

K. Irvine, N. Restifo, M. Wang, 1994, Folia biologica.

Mining the mutanome: developing highly personalized Immunotherapies based on mutational analysis of tumors

F. Marincola, H. Rammensee, E. Wang, 2013, Journal of Immunotherapy for Cancer.

Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity

S. Rosenberg, D. Powell, R. Nussenblatt, 2008, Proceedings of the National Academy of Sciences.

Customizing Functionality and Payload Delivery for Receptor-Engineered T Cells

C. Klebanoff, N. Restifo, 2016, Cell.

Highlights of the society for immunotherapy of cancer (SITC) 27th annual meeting

F. Marincola, R. Puri, L. Zitvogel, 2013, Journal of Immunotherapy for Cancer.

Programming CD8+ T cells for effective immunotherapy.

N. Restifo, L. Gattinoni, Christian S. Hinrichs, 2006, Current opinion in immunology.

Use of standard criteria for assessment of cancer vaccines.

S. Rosenberg, N. Restifo, 2005, The Lancet. Oncology.

Reply to "Cancer vaccines: pessimism in check"

S. Rosenberg, J. Yang, N. Restifo, 2004, Nature Medicine.

Poor immunogenicity of a self/tumor antigen derives from peptide-MHC-I instability and is independent of tolerance.

B. Baker, N. Restifo, D. Surman, 2004, The Journal of clinical investigation.

Antigen processing in vivo and the elicitation of primary CTL responses.

R. Anderson, J. Yewdell, J. Bennink, 1995, Journal of immunology.

Cell Transfer Therapy for Cancer: Lessons from Sequential Treatments of a Patient With Metastatic Melanoma

Steven A. Rosenberg, Douglas J. Schwartzentruber, S. Rosenberg, 2003, Journal of immunotherapy.

Antisense targeting of CD47 enhances human cytotoxic T-cell activity and increases survival of mice bearing B16 melanoma when combined with anti-CTLA4 and tumor irradiation

L. Ridnour, D. Roberts, N. Restifo, 2019, Cancer Immunology, Immunotherapy.

Treatment of tumors with CD 4 + T cells Muranski and Restifo 201 Th cells in cancer immunity

P. Muranski, N. Restifo, 2009 .

DNA vaccines and apoptosis: to kill or not to kill?

N. Restifo, W. Leitner, 2003, The Journal of clinical investigation.

Identification of a Kb-restricted CTL epitope of beta-galactosidase: potential use in development of immunization protocols for "self" antigens.

N. Restifo, D. Surman, W. Overwijk, 1997, Methods.

Insertion signal sequence fused to minimal peptides elicits specific CD8+ T-cell responses and prolongs survival of thymoma-bearing mice.

S. Rosenberg, N. Restifo, P. Spiess, 1994, Cancer research.

A Three-dimensional Thymic Culture System to Generate Murine Induced Pluripotent Stem Cell-derived Tumor Antigen-specific Thymic Emigrants.

T. Maeda, N. Restifo, Li Jia, 2019, Journal of visualized experiments : JoVE.

Altered CD8+ T-Cell Responses When Immunizing With Multiepitope Peptide Vaccines

S. Rosenberg, J. Yang, S. Topalian, 2006, Journal of immunotherapy.

Multi-phenotype CRISPR-Cas9 Screen Identifies p38 Kinase as a Target for Adoptive Immunotherapies.

N. Restifo, D. Palmer, Li Jia, 2020, Cancer cell.

Immunotherapy Bridge 2016 and Melanoma Bridge 2016: meeting abstracts

C. Croce, L. Fattore, R. Mancini, 2017, Journal of Translational Medicine.

Does IL-17 promote tumor growth?

P. Muranski, N. Restifo, 2009, Blood.

Viral Sequestration of Antigen Subverts Cross Presentation to CD8+ T Cells

J. M. Grant, N. Restifo, D. Palmer, 2009, PLoS pathogens.

Response to Comment on “Tumor Progression Can Occur despite the Induction of Very High Levels of Self/Tumor Antigen-Specific CD8+ T Cells in Patients with Melanoma”

S. Rosenberg, N. Restifo, 2006, The Journal of Immunology.

Toll-like receptor agonist therapy can profoundly augment the antitumor activity of adoptively transferred CD8+ T cells without host preconditioning

N. Restifo, Claudia Wrzesinski, C. Paulos, 2016, Journal of Immunotherapy for Cancer.

Immunotherapy: Treatment of aggressive lymphomas with anti-CD19 CAR T cells

C. Klebanoff, N. Restifo, Tori N. Yamamoto, 2014, Nature Reviews Clinical Oncology.

370 The Epi-RTMtechnology produces a polyclonal TIL product (LYL845) with a greater expansion success rate across hot and cold tumors, improved product phenotype, and maintenance of TCR diversity

S. Potluri, M. Casas, P. Sundar, 2022, Regular and Young Investigator Award Abstracts.

Multiply restimulated human thymic regulatory T cells express distinct signature regulatory T-cell transcription factors without evidence of exhaustion.

J. Wagner, S. Furlan, E. Wang, 2021, Cytotherapy.

Induction of tumor antigen-specific immunity in vivo by a novel vaccinia vector encoding safety-modified simian virus 40 T antigen.

M. Sanda, J. Mulé, M. Imperiale, 1999, Journal of the National Cancer Institute.

A cleavage product of Polycystin-1 is a mitochondrial matrix protein that affects mitochondria morphology and function when heterologously expressed

G. Germino, W. Prinz, T. Watnick, 2018, Scientific Reports.

Transcriptional profiles reveal a stepwise developmental program of memory CD8(+) T cell differentiation.

G. Nabel, C. Klebanoff, R. Sékaly, 2015, Vaccine.

The multiple uses of viruses for studying antigen processing

J. Yewdell, J. Bennink, L. Eisenlohr, 1993 .

Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts

Michael F. Sharpnack, D. Schadendorf, R. Sullivan, 2018, Journal of Translational Medicine.

Phase I S tudy o f t he I ntravenous A dministration o f Attenuated Salmonella t yphimurium to P atients W ith Metastatic M elanoma

F. Marincola, S. Rosenberg, P. Hwu, 2002 .

The antiviral enzymes PKR and RNase L suppress gene expression from viral and non-viral based vectors.

B. Williams, R. Silverman, N. Restifo, 1999, Nucleic acids research.

The Cish SH2 domain is essential for PLC-γ1 regulation in TCR stimulated CD8+ T cells

V. Barr, Ana Dios-Esponera, L. Samelson, 2018, Scientific Reports.

Identification of Small Molecule Enhancers of Immunotherapy for Melanoma

M. Ferrer, Noel Southall, A. Jadhav, 2020, Scientific Reports.

Tumor-specific Th17-polarized cells eradicate large established melanoma.

P. Muranski, K. Irvine, N. Restifo, 2008, Blood.

Type I Cytokines Synergize with Oncogene Inhibition to Induce Tumor Growth Arrest

James J. Morrow, F. Marincola, M. Raffeld, 2014, Cancer Immunology Research.

gp100/pmel 17 Is a Murine Tumor Rejection Antigen: Induction of “Self”-reactive, Tumoricidal T Cells Using High-affinity, Altered Peptide Ligand

B. Moss, S. Rosenberg, K. Irvine, 1998, The Journal of experimental medicine.

Th17 cells are long lived and retain a stem cell-like molecular signature.

R. Danner, P. Muranski, C. Klebanoff, 2011, Immunity.

Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells.

T. Waldmann, S. Rosenberg, C. Klebanoff, 2005, Proceedings of the National Academy of Sciences of the United States of America.

Classification of Current Anticancer Immunotherapies Classification of Current Anticancer Immunotherapies , Maha Ayyoub , Philipp Beckhove , Chiara Castelli

S. H. van der Burg, A. Palucka, M. Dhodapkar, 2022 .

Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts.

G. Trinchieri, S. Rosenberg, P. Muranski, 2010, Cancer research.

Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function.

P. Muranski, C. Klebanoff, A. Lal, 2013, The Journal of clinical investigation.

Suppressors of cytokine signaling (SOCS) in T cell differentiation, maturation, and function.

N. Restifo, D. Palmer, 2009, Trends in immunology.

Identification, isolation and in vitro expansion of human and nonhuman primate T stem cell memory cells

M. Roederer, E. Lugli, N. Restifo, 2012, Nature Protocols.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Charles J. Vaske, Joe Y. Chang, Scott R. Presnell, 2016, Journal for ImmunoTherapy of Cancer.